Trial Profile
A Study Assessing Anti-Cyclic Citrullinated Peptide (Anti-CCP) as an Independent Predictor of 12-Month EULAR Response in Patients with Rheumatoid-Arthritis Treated with Abatacept
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jul 2017
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 14 Jul 2017 New trial record
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism.